Tsc1 — Tuberous Sclerosis Complex 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tuberous Sclerosis Complex 1 (TSC1) encodes the protein hamartin, a crucial tumor suppressor protein that plays essential roles in cell growth, proliferation, and synaptic function. Mutations in TSC1 cause tuberous sclerosis complex, a genetic disorder characterized by benign tumors (hamartomas) throughout the body, including the brain, where they can cause seizures, developmental delays, and increased risk of neurodegenerative processes.
| Property | Value |
|---|---|
| Gene Symbol | TSC1 |
| Full Name | Tuberous Sclerosis Complex 1 |
| Chromosomal Location | 9q34 |
| NCBI Gene ID | 7248 |
| Ensembl ID | ENSG00000115159 |
| OMIM ID | 191100 |
| UniProt ID | Q9UPZ6 |
| Protein Name | Hamartin |
| Molecular Weight | ~130 kDa |
Hamartin is a 1,164 amino acid protein primarily localized to the cytoplasm and plasma membrane. It contains several functional domains including a hamartin elbow domain (HED), a transmembrane region, and a conserved tuberous sclerosis complex domain (TSC-TBD)[1]. Hamartin forms a heterodimer with TSC2 (tuberin), which is essential for their tumor suppressor function.
The TSC1/TSC2 complex serves as a critical regulator of the mTOR (mechanistic target of rapamycin) signaling pathway, a central regulator of cell growth and metabolism. The TSC1-TSC2 complex acts as a GTPase-activating protein (GAP) toward Rheb (Ras homolog enriched in brain), inhibiting mTORC1 activity when cellular energy levels are low or growth factors are scarce[2]. When TSC1 is functional, it helps maintain mTOR signaling homeostasis, ensuring proper protein synthesis, autophagy, and cell growth.
Beyond its role in cell growth, TSC1 is expressed in neurons and plays important roles in synaptic plasticity, dendritic spine morphology, and neuronal connectivity. TSC1 haploinsufficiency affects synaptic function and can lead to altered long-term potentiation (LTP) and learning deficits in mouse models[3].
Tuberous sclerosis complex is an autosomal dominant genetic disorder caused by heterozygous pathogenic variants in either TSC1 or TSC2. It affects approximately 1 in 6,000-10,000 live births and has a birth incidence of about 1 in 5,800[4]. The disease is characterized by:
Recent research has revealed connections between TSC1 dysfunction and neurodegenerative processes:
The mTOR inhibitor everolimus has shown efficacy in treating TSC-related tumors and epilepsy, highlighting the importance of mTOR pathway modulation in this disorder[6]. Rapamycin and its analogs are now standard treatments for SEGAs and renal angiomyolipomas in TSC patients.
Hamartin is expressed in most human tissues, with high expression in:
In the brain, TSC1 is expressed in neurons, astrocytes, and oligodendrocytes, with particular importance in synaptic compartments.
The study of Tsc1 — Tuberous Sclerosis Complex 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
van Slegtenhorst M, et al. (1997). Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 277(5327):805-808. PMID:9242607
Tee AR, et al. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit and stimulate mTOR. Current Biology. 12(9):703-711. PMID:12007410
Ehninger D, et al. (2008). Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nature Medicine. 14(8):843-848. PMID:18568033
Osborne JP, et al. (1991). Epidemiology of tuberous sclerosis. Annals of the New York Academy of Sciences. 615:125-127. PMID:2037612
Citrigno L, et al. (2020). mTOR Dysregulation and Therapeutic Targets in Tuberous Sclerosis Complex. Journal of Clinical Medicine. 9(11):3540. PMID:33171677
Franz DN, et al. (2013). Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the EXIST-1 trial. Lancet Oncology. 14(9):839-848. PMID:23810380
Nie D, et al. (2010). Tsc1 deficiency compromises hippocampal dendritic spine polarity and transport. Nature Neuroscience. 13(5):551-558. PMID:20383140
Kwiatkowski DJ, et al. (2002). Tuberous sclerosis: what's new? Trends in Neurosciences. 25(7):379-381. PMID:12086760